EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology

Alex T Larsson iD, Himanshi Bhatia, Ana Calizo, Kai Pollard, Xiaochun Zhang, Eric Conniff, Justin F Tibbitts, Elizabeth Rono, Katherine Cummins, Sara H Osum, Kyle B Williams, Alexandra L Crampton und 16 weitere

Neuro-Oncology · 2023

DOI: 10.1093/neuonc/noad097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Alex T Larsson und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Neurofibrosarcoma, Neurofibromatosis 1, Nerve Sheath Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft tissue sarcomas that often develop in patients with neurofibromatosis type 1 (NF1). To address the critical need for novel therapeutics in MPNST, we aimed to establish an ex vivo 3D platform that accurately captured the genomic diversity of MPNST and could be utilized in a medium-throughput manner for drug screening studies to be validated in vivo using patient-derived xenografts (PDX).

Methods

Genomic analysis was performed on all PDX-tumor pairs. Selected PDX were harvested for assembly into 3D microtissues. Based on prior work in our labs, we evaluated drugs (trabectedin, olaparib, and mirdametinib) ex vivo and in vivo. For 3D microtissue studies, cell viability was the endpoint as assessed by Zeiss Axio Observer. For PDX drug studies, tumor volume was measured twice weekly. Bulk RNA sequencing was performed to identify pathways enriched in cells.

Results

We developed 13 NF1-associated MPNST-PDX and identified mutations or structural abnormalities in NF1 (100%), SUZ12 (85%), EED (15%), TP53 (15%), CDKN2A (85%), and chromosome 8 gain (77%). We successfully assembled PDX into 3D microtissues, categorized as robust (>90% viability at 48 h), good (>50%), or unusable (<50%). We evaluated drug response to “robust” or “good” microtissues, namely MN-2, JH-2-002, JH-2-079-c, and WU-225. Drug response ex vivo predicted drug response in vivo, and enhanced drug effects were observed in select models.

Conclusions

These data support the successful establishment of a novel 3D platform for drug discovery and MPNST biology exploration in a system representative of the human condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeurofibrosarcomaNeurofibromatosis 1Nerve Sheath NeoplasmsHumansPrecision MedicineMutation

Stichwörter der Autor:innen

3D microtissuesMPNSTNF1PDXdrug screeninggenomic variants

Autor:innen und Institutionen

  • Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.
  • Division of Oncology, Department of Internal Medicine, Siteman Cancer Center, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Department of Oncology and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota, USA.
  • Pacific Northwest National Laboratory, Seattle, Washington, USA.
  • Department of Pathology, Division of Surgical Pathology, Johns Hopkins Hospital, Baltimore, Maryland, USA.

ORCID-Profile: Alex T Larsson, Angela C Hirbe

Förderung

  • NINDS NIH HHS
  • NCI NIH HHS

Zitieren

APA

Larsson, A. T., Bhatia, H., Calizo, A., Pollard, K., Zhang, X., Conniff, E., Tibbitts, J. F., Rono, E., Cummins, K., Osum, S. H., Williams, K. B., Crampton, A. L., Jubenville, T., Schefer, D., Yang, K., Lyu, Y., Pino, J. C., Bade, J., Gross, J. M., …, & Hirbe, A. C. (2023). Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad097

Vancouver

Larsson AT, Bhatia H, Calizo A, Pollard K, Zhang X, Conniff E, et al. Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. Neuro-Oncology. 2023. doi:10.1093/neuonc/noad097

BibTeX
@article{Larsson2023,
  author = {Larsson, Alex T and Bhatia, Himanshi and Calizo, Ana and Pollard, Kai and Zhang, Xiaochun and Conniff, Eric and Tibbitts, Justin F and Rono, Elizabeth and Cummins, Katherine and Osum, Sara H and Williams, Kyle B and Crampton, Alexandra L and Jubenville, Tyler and Schefer, Daniel and Yang, Kuangying and Lyu, Yang and Pino, James C and Bade, Jessica and Gross, John M and Lisok, Alla and Dehner, Carina A and Chrisinger, John S A and He, Kevin and Gosline, Sara J C and Pratilas, Christine A and Largaespada, David A and Wood, David K and Hirbe, Angela C},
  title = {Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology},
  journal = {Neuro-Oncology},
  year = {2023},
  doi = {10.1093/neuonc/noad097}
}
Kostenlos starten →